A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
about
Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsImmediate effect of intravitreal injection of bevacizumab on intraocular pressure.New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration.Three-dimensional segmentation of fluid-associated abnormalities in retinal OCT: probability constrained graph-search-graph-cutCommon variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration.Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes.Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.[Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
P2860
Q33911625-7B636E69-17CA-4B4B-A729-47AF8F25542EQ33968693-AEEE4A45-122E-48BE-AA9A-E6CEBC370AD4Q35838282-06D402AD-DC8A-470D-A8FB-95B106AD95E6Q36861916-23063617-6620-4A54-8AD7-B28A0379593FQ37246901-B3192FC0-6A50-466A-B5CC-43563EAD0EFBQ37361026-073C6108-632A-49D3-A270-84B9779C209EQ37498854-F3502202-78F7-48EC-AD71-E66389680C5AQ37792817-97A93E23-B539-4EEF-8E68-B89F0B484089Q38764072-356A3D8E-7750-43FC-B831-8A2313A9472DQ38867756-31F2D5C6-7C3A-4E8C-BD0D-22027777C588Q39965612-40684AB1-48F7-4E7D-8F0C-D4C0C8386961Q41558337-2D5405D6-5CAA-4669-847A-150B4D86E17AQ44680785-A684A4C5-2FDE-486E-9FEB-61EE1A716AB9Q47864131-D62AE1E6-B900-4077-BDBA-B38A028AE512
P2860
A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A prospective study on intravi ...... ration of different durations.
@ast
A prospective study on intravi ...... ration of different durations.
@en
A prospective study on intravitreal bevacizumab
@nl
type
label
A prospective study on intravi ...... ration of different durations.
@ast
A prospective study on intravi ...... ration of different durations.
@en
A prospective study on intravitreal bevacizumab
@nl
prefLabel
A prospective study on intravi ...... ration of different durations.
@ast
A prospective study on intravi ...... ration of different durations.
@en
A prospective study on intravitreal bevacizumab
@nl
P2093
P1433
P1476
A prospective study on intravi ...... ration of different durations.
@en
P2093
Anders Kvanta
Björn Steén
Peep V Algvere
Stefan Seregard
P304
P356
10.1111/J.1600-0420.2007.01113.X
P577
2007-12-14T00:00:00Z